Heterodimeric antibodies that bind CD3 and GPC3
US11859012B2 · kind B2 · utility
0Cited by
130References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2022 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Mar 10, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.